Zhitong Finance App News, Baili Tianheng (688506.SH) issued an announcement. The company recently received the “Drug Clinical Trial Approval Notice” officially approved and issued by the National Drug Administration (NMPA), and the clinical trial of BL-M12D1 (ADC) for injectable innovative biopharmaceuticals independently developed by the company was approved. BL-M12D1 for injection is an ADC drug that comes from the same technology platform as iza-Bren and shares the same “connector+toxin” platform with Yizekang® (bl-B01D1/iza-Bren). Its indications are recurrent or refractory hematologic malignancies.

Zhitongcaijing · 1d ago
Zhitong Finance App News, Baili Tianheng (688506.SH) issued an announcement. The company recently received the “Drug Clinical Trial Approval Notice” officially approved and issued by the National Drug Administration (NMPA), and the clinical trial of BL-M12D1 (ADC) for injectable innovative biopharmaceuticals independently developed by the company was approved. BL-M12D1 for injection is an ADC drug that comes from the same technology platform as iza-Bren and shares the same “connector+toxin” platform with Yizekang® (bl-B01D1/iza-Bren). Its indications are recurrent or refractory hematologic malignancies.